Search for 'an:"302" and itype:COM'

18F-FDG PET-CT Predicting Pathological Response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer.

By Sánchez Fuentes, Diana | Pedraza Fernández, Sara | Ruiz Solís, Sebastián | Hernández Martínez, Ana Cristina | Sarandeses Fernández, Pilar | Gómez Grande, Adolfo | Pérez Escutia, Mª Ángeles | Estenoz Alfaro, Juana María. European journal of nuclear medicine and molecular imaging, 2015 . 42 Suppl 1:666. , Formato Vancouver: Sánchez Fuentes D, Pedraza Fernández S, Ruiz Solis S, Hernández Martínez A, Sarandeses Fernández P, Gómez Grande A et al. 18F-FDG PET-CT Predicting Pathological Response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer. En: EANM'15, 28th Annual EANM Congress of the European Association of Nuclear Medicine 2015. Hamburg, Germany. Eur J Nucl Med Mol Imaging. 2015 Oct;42 Suppl 1:666.

Place Hold on 18F-FDG PET-CT Predicting Pathological Response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer.

Late Side Effects in Men With Intermediate- and High-RiskProstate Cancer Treated With High-Dose Radiation Therapy andAndrogen Deprivation (DART 01/05): Secondary Endpoints Froma Phase 3 Clinical Trial.

By Cabeza Rodríguez, Mª Ángeles. International Journal of Radiation Oncology Biology Physics, 2013 . 87(2):S105. , Formato Vancouver: Zapatero A, Guerrero A, Maldonado X, Álvarez A, San Segundo CG, Cabeza M, et al. Late side effects in men with intermediate- and high-risk prostate cancer treated with high-dose radiation therapy and androgen deprivation (DART 01/05): Secondary endpoints from a phase 3 clinical trial. Int J Radiat Oncol Biol Phys. 2013;87(2):S105 [Annual Meeting of the American Society for Radiation Oncology (55. 2013. Atlanta, GA.)]

Place Hold on Late Side Effects in Men With Intermediate- and High-RiskProstate Cancer Treated With High-Dose Radiation Therapy andAndrogen Deprivation (DART 01/05): Secondary Endpoints Froma Phase 3 Clinical Trial.